Skip to main content
main-content

Latest news stories

Latest news stories

03-17-2019 | Canagliflozin | News

Canagliflozin may reduce HF events irrespective of ejection fraction

A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.

03-15-2019 | Medication adherence | News

Targeted insulin-adherence intervention may improve glycemic control

Targeting specific populations of individuals with type 2 diabetes for intensive interventions to optimize their insulin use may result in better glycemic control than an untargeted approach, findings from the TARGIT-Diabetes trial suggest.

03-14-2019 | Hypoglycemia | News

Real-world hypoglycemia data support continued sulfonylurea role in type 2 diabetes

Hypoglycemia is common among people being treated for type 2 diabetes, particularly those using insulin or a sulfonylurea, but the risk for severe episodes is only elevated among insulin users, suggest results of a prospective UK study.

03-13-2019 | Canagliflozin | DUKPC 2019 | News

ABCD audit data reveal improved glycemic control with use of FreeStyle Libre, canagliflozin

Analyses of real-world audit data show positive initial results for the flash glucose monitoring system FreeStyle Libre and the sodium-glucose cotransporter 2 inhibitor canagliflozin.

03-13-2019 | Psychosocial care | News

Tailored CBT reduces depression, distress in type 2 diabetes

A patient-specific cognitive behavioral therapy and lifestyle counseling intervention can significantly improve psychological outcomes in type 2 diabetes patients with depression and/or regimen-related distress, say researchers.

03-12-2019 | Medications | DUKPC 2019 | News

Adding second diabetes medication better than switching in face of poor response

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

03-12-2019 | Hypoglycemia | DUKPC 2019 | News

Nurse-led intervention can reduce mortality risk after severe hypoglycemia

Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.

03-11-2019 | Pregnancy | DUKPC 2019 | News

Autoantibodies in pregnancy signal high risk for impending type 1 diabetes

Women with gestational diabetes who also have autoantibodies are highly likely to go on and develop type 1 diabetes, research shows.

03-11-2019 | Cardiovascular disorders | News

Modifiable cardiometabolic risk factors dominant type 1 diabetes mortality risk

The strongest predictors for mortality and cardiovascular disease disease in patients with type 1 diabetes are generally modifiable cardiometabolic risk factors, researchers report.

03-08-2019 | Pregnancy | DUKPC 2019 | News

CONCEPTT data show substantial cost savings with CGM in pregnancy

Using continuous glucose monitoring for all women with type 1 diabetes during pregnancy could save the UK National Health Service over 9 million pounds per year, report the CONCEPTT investigators.

03-08-2019 | Obesity | News

Similar weight-loss outcomes with one anastomosis, Roux-en-Y gastric bypass procedures

Findings from the YOMEGA trial indicate that the one anastomosis gastric bypass procedure is noninferior to standard Roux-en-Y gastric bypass in terms of weight loss and metabolic outcomes.

03-08-2019 | Diagnosis | DUKPC 2019 | News

TrialNet monitoring study shows risk-reducing effect of type 1 diabetes screening

Data from the TrialNet Pathway to Prevention study shows that monitoring high-risk relatives of people with type 1 diabetes markedly reduces the risk for those who develop the condition presenting with diabetic ketoacidosis.

03-07-2019 | Diagnosis | DUKPC 2019 | News

Double-checking C-peptide well after type 1 diagnosis can lead to reclassifications

Measuring C-peptide in everyone a minimum of 3 years after a clinical diagnosis of type 1 diabetes can result in some people being reclassified with other forms of diabetes, researchers report.

03-07-2019 | Diabetes prevention | DUKPC 2019 | News

UK diabetes prevention update underscores importance of program retention

The latest update from the UK’s National Health Service Diabetes Prevention Programme shows that persistence pays, and reveals weight loss and a reduction in glycated hemoglobin levels for people who have so far completed the intervention.

03-06-2019 | Diet | DUKPC 2019 | News

Diabetes remission durable for a third of DiRECT participants

Just over a third of people who undertook a period on a very-low-calorie diet in the DiRECT trial to tackle type 2 diabetes are in remission 24 months later, the investigators have reported.

03-05-2019 | Physical activity | Highlight | News

Behavioral intervention has durable physical activity effect in type 2 diabetes

A behavioral intervention has lasting effects on physical activity levels, fitness, and vascular risk in people with type 2 diabetes, show the 3-year results of the randomized Italian Diabetes and Exercise Study 2.

03-05-2019 | Semaglutide | News

SUSTAIN 9 supports semaglutide, SGLT2 inhibitor combination

Adding the glucagon-like peptide-1 analog semaglutide to an existing sodium-glucose cotransporter 2 inhibitor improves glycemic control and bodyweight in patients with poorly controlled type 2 diabetes, SUSTAIN 9 data show.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

02-28-2019 | Insulin | News

Real-world HbA1c targets usually individualized, rarely achieved

Real-world data show that people with type 2 diabetes struggle to attain their glycated hemoglobin targets, despite these commonly being individualized.

02-28-2019 | Mobile technology | News

Engagement with mobile health intervention linked to improved glycemic control

Responsiveness to text message reminders about blood glucose monitoring is associated with glycemic benefit among adolescents with type 1 diabetes, study findings indicate.

image credits